Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice

Li,Wei; Xu,Xiao-Li; Zhang,Jun; Cai,Jia-Hui; Tang,Yun-Xian

doi:10.3892/ol.2012.929

Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice

Authors:
- Wei Li
- Xiao-Li Xu
- Jun Zhang
- Jia-Hui Cai
- Yun-Xian Tang
View Affiliations

Affiliations: Department of Gynecology, Nanjing Medical University of Hangzhou Hospital, Hangzhou, Zhejiang 310006, P.R. China
Published online on: September 20, 2012 https://doi.org/10.3892/ol.2012.929
Pages: 1269-1273

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed to investigate whether cyclooxygenase (COX) inhibitors (coxibs) could prolong survival time by attenuating the tumor growth of ovarian cancer xenograft‑bearing mice. Tumor growth and survival time were observed and compared in mice which were treated with a COX‑1 inhibitor (SC‑560) and a COX‑2 inhibitor (celecoxib) every other day for a 21 day period from the day of tumor formation. The trial lasted a total of 121 days. The combination therapy resulted in statistically significant inhibition of tumor size compared with the control group (P<0.05). Additionally, single treatment of SC‑560 or celecoxib significantly prolonged the mean survival time of mice compared with the control group (P<0.05). We suggest that COX‑1 and COX‑2 inhibitors may improve survival and inhibit tumor growth, and that the tumor growth inhibition by coxibs may be the contributing factor for the prolonged survival time in mouse xenograft models.

View Figures

View References

1.	WL SmithRM GaravitoDL DeWittProstaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2J Biol Chem2713315733160199610.1074/jbc.271.52.331578969167
2.	RA GuptaRN DuboisColorectal cancer prevention and treatment by inhibition of cyclooxygenase-2Nat Rev Cancer11121200110.1038/3509401711900248
3.	RA SoslowAJ DannenbergD RushBM WoernerKN KhanJ MasferrerAT KokiCOX-2 is expressed in human pulmonary, colonic, and mammary tumorsCancer8926372645200010.1002/1097-0142(20001215)89:12%3C2637::AID-CNCR17%3E3.0.CO;2-B11135226
4.	C DenkertM KobelS PestI KochS BergerM SchwabeA SiegertA RelesB KlosterhalfenS HauptmannExpression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinomaAm J Pathol160893903200210.1016/S0002-9440(10)64912-711891188
5.	BM ErovicM WoegerbauerJ PammerE SelzerMCh GraslD ThurnherStrong evidence for up-regulation of cyclooxygenase-1 in head and neck cancerEur J Clin Invest386166200810.1111/j.1365-2362.2007.01896.x18173552
6.	T DaikokuD WangS TranguchJD MorrowS OrsulicRN DuboisSK DeyCyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancerCancer Res6537353744200510.1158/0008-5472.CAN-04-381415867369
7.	G SteinbachPM LynchRK PhillipsMH WallaceE HawkGB GordonN WakabayashiB SaundersY ShenT FujimuraLK SuB LevinThe effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposisN Engl J Med34219461952200010.1056/NEJM20000629342260310874062
8.	BT RagelRL JensenDL GillespieSM PrescottWT CouldwellCelecoxib inhibits meningioma tumor growth in a mouse xenograft modelCancer109588597200710.1002/cncr.2244117177201
9.	M YaoS KargmanEC LamCR KellyY ZhengE KwongJF EvansMM WolfeInhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in miceCancer Res63586592200312566300
10.	ME UrickJR GilesPA JohnsonVEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancerGynecol Oncol110418424200810.1016/j.ygyno.2008.05.01818606441
11.	NK AltorkiP ChristosJL PortPC LeeF MirzaC SpinelliR KeresztesD BeneckS PaulBM StilesY ZhangDS SchrumpPreoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trialJ Thorac Oncol611211127201110.1097/JTO.0b013e31821529a921532508
12.	M SenzakiS IshidaA YadaM HanaiK FujiwaraS InoueT KimuraS KurakateCS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agentsInt J Cancer12213841390200810.1002/ijc.23250
13.	B XinY YokoyamaT ShigetoH MizunumaAnti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancersPathol Oncol Res13365369200710.1007/BF0294031818158574
14.	J ReeseX ZhaoWG MaN BrownTJ MaziaszSK DeyComparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in miceEndocrinology14231983206200111416042
15.	CS WilliamsAJ WatsonH ShengR HelouJ ShaoRN DuboisCelecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo modelsCancer Res6060456051200011085526
16.	YW JungSW KimS KimJH KimNH ChoJW KimYT KimPrevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinomaEur J Obstet Gynecol Reprod Biol1486266201010.1016/j.ejogrb.2009.09.01119836124
17.	SA GlynnRL PrueittLA RidnourBJ BoersmaTM DorseyDA WinkJE GoodmanHG YfantisDH LeeS AmbsCOX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancerBMC Cancer10626201010.1186/1471-2407-10-62621078168
18.	TL ErkinheimoH LassusP FinneBP van ReesA LeminenO YlikorkalaC HaglundR ButzowA RistimäkiElevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinomaClin Cancer Res10538545200410.1158/1078-0432.CCR-0132-0314760075
19.	KU SorenmoMH GoldschmidtFS ShoferC GoldkampJ FerraconeEvaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinomaVet Comp Oncol21323200410.1111/j.1476-5810.2004.00035.x19379307
20.	W LiJ WangHR JiangXL XuJ ZhangML LiuLY ZhaiCombined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivoInt J Mol Sci12668681201110.3390/ijms1201066821340007
21.	T KitamuraM ItohT NodaM MatsuuraK WakabayashiCombined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout miceInt J Cancer109576580200410.1002/ijc.2001214991580
22.	W LiHR JiangXL XuJ WangJ ZhangML LiuLY ZhaiCyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivoInt J Mol Sci1139994013201010.3390/ijms1110399921152316
23.	M YaoW ZhouS SanghaA AlbertAJ ChangTC LiuMM WolfeEffects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancerClin Cancer Res1116181628200510.1158/1078-0432.CCR-04-169615746067
24.	DB HalesY ZhugeJA LagmanK AnsenbergerC MahonA BaruaJL LuborskyJM BahrCyclooxygenases expression and distribution in the normal ovary and their role in ovarian cancer in the domestic hen (Gallus domesticus)Endocrine33235244200810.1007/s12020-008-9080-z18498063
25.	F SpinellaL RosanoV Di CastroMR NicotraPG NataliA BagnatoInhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cellsClin Cancer Res1046704679200410.1158/1078-0432.CCR-04-031515269139
26.	H ShengJ ShaoJD MorrowRD BeauchampRN DuBoisModulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cellsCancer Res5836236619989443418
27.	JL MasferrerKM LeahyAT KokiBS ZweifelSL SettleBM WoernerDA EdwardsAG FlickingerRJ MooreK SeibertAntiangiogenic and antitumor activities of cyclooxygenase-2 inhibitorsCancer Res6013061311200010728691